Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- About
iShares Trust - iShares Neuroscience and Healthcare ETF (IBRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: IBRN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type ETF | Historic Profit 47.07% | Avg. Invested days 65 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Volume (30-day avg) - | Beta - | 52 Weeks Range 17.86 - 28.63 | Updated Date 06/29/2025 |
52 Weeks Range 17.86 - 28.63 | Updated Date 06/29/2025 |
Upturn AI SWOT
iShares Trust - iShares Neuroscience and Healthcare ETF
ETF Overview
Overview
The iShares Neuroscience and Healthcare ETF (IBB) seeks to track the investment results of an index composed of U.S. equities in the neuroscience and healthcare sectors, providing targeted exposure to companies involved in these innovative fields. It aims for capital appreciation through investments in companies that research, develop, manufacture, and distribute neuroscience and healthcare products and services.
Reputation and Reliability
BlackRock, the issuer of iShares ETFs, is one of the world's largest asset managers, known for its extensive experience and reliability in providing investment solutions.
Management Expertise
BlackRock has a dedicated team of investment professionals with extensive experience in managing ETFs and sector-specific portfolios.
Investment Objective
Goal
The investment objective of IBB is to track the investment results of an index composed of U.S. equities in the neuroscience and healthcare sectors.
Investment Approach and Strategy
Strategy: The ETF employs a passive management investment strategy, seeking to track the performance of its underlying index by investing in its constituent securities in similar proportions.
Composition The ETF holds a diversified portfolio of stocks primarily focused on the healthcare and neuroscience sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services companies.
Market Position
Market Share: IBB holds a significant but not dominant market share in the healthcare and biotech ETF space, facing competition from other similar ETFs.
Total Net Assets (AUM): 308000000
Competitors
Key Competitors
- XBI
- XLV
- FBT
Competitive Landscape
The healthcare ETF industry is competitive, with IBB facing competition from broad healthcare ETFs (XLV), and other biotech-focused ETFs (XBI, FBT). IBB's advantage lies in its specific focus on neuroscience, but it is less diversified than broad healthcare ETFs. Other Biotech ETFs (XBI, FBT) have outperformed it recently due to sector preference.
Financial Performance
Historical Performance: Historical performance varies depending on the time period. Please refer to reputable financial data sources for specific figures.
Benchmark Comparison: The ETF's performance should be compared to its underlying index, usually specified in the fund prospectus.
Expense Ratio: 0.47
Liquidity
Average Trading Volume
IBB typically has a high average trading volume, indicating good liquidity.
Bid-Ask Spread
The bid-ask spread for IBB is generally tight, reflecting its high trading volume.
Market Dynamics
Market Environment Factors
Economic indicators, healthcare policy changes, pharmaceutical innovation, and biotechnology advancements can all affect IBB. These factors shape the investment climate and influence performance.
Growth Trajectory
IBB's growth trajectory depends on the overall performance of the healthcare and biotech sectors, particularly companies involved in neuroscience. Changes in healthcare regulations or scientific breakthroughs will impact the sector as a whole.
Moat and Competitive Advantages
Competitive Edge
IBB's competitive advantage stems from its brand recognition as an iShares ETF and its targeted exposure to the neuroscience and healthcare sectors. It provides investors with a convenient way to access a specific segment of the healthcare industry. Its access to Neuroscience industry gives it slightly better niche than general Biotech ETFs. The fund can give better returns when that sector is favored.
Risk Analysis
Volatility
IBB can exhibit moderate to high volatility, reflecting the inherent risk in the healthcare and biotechnology sectors.
Market Risk
Specific risks include regulatory changes, patent expirations, clinical trial failures, and overall market sentiment towards the healthcare and biotech industries.
Investor Profile
Ideal Investor Profile
IBB is suitable for investors who want targeted exposure to the healthcare and neuroscience sectors and are willing to accept a moderate to high level of risk.
Market Risk
IBB can be suitable for both long-term investors seeking growth and active traders looking to capitalize on short-term market movements.
Summary
IBB is an iShares ETF providing targeted exposure to the neuroscience and healthcare sectors. Its performance is influenced by healthcare policies, scientific advancements, and overall market sentiment. The ETF has good liquidity and provides a cost-effective way to invest in this specialized area of the healthcare industry. Its risk profile is moderate to high, making it suitable for investors with some risk tolerance.
Similar ETFs
Sources and Disclaimers
Data Sources:
- iShares Official Website
- Yahoo Finance
- Bloomberg
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iShares Trust - iShares Neuroscience and Healthcare ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.